CD4 and neoplasm: Although anti-PD1 antibodies primarily target T cells, B and CD4+ T cells were essential in ICB-driven anti-tumor responses via secreting antibody and helping T cell response, as indicated by depletion of B cells significantly reduced therapeutic response to anti-PD1 in mice model52.